This article was originally published in The Tan Sheet
FDA clarifies pre-emption on OTC labeling
You may also be interested in...
A report by a Johnson & Johnson special committee finds organizational and middle management changes at the firm were the root causes of manufacturing and quality control lapses in the OTC drug business.
Merck & Co. announced Nov. 30 it promoted current president Kenneth Frazier to CEO effective Jan. 1.
FDA has not altered its support of pre-emption in product liability suits but there are signs it will happen under the Obama administration